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Osteoporosis is a disease characterized by decreased bone mass and deterioration of bone 
microarchitecture. It is a highly prevalent condition in western countries, and it is estimated 
to affect 5 % of the Portuguese population. Advances in the research in the pathophysiology 
of the disease have been used for the development of new molecules. In addition, several 
clinical trials have been developed in order to determine the effectiveness of new drugs to 
treat osteoporosis. 
The aim of this study was to systematically review randomized controlled trials of oral 
drugs for osteoporosis treatment. The systematic review was performed in electronic 
databases, particularly at Clinical- Trials (www.clinicaltrials.gov) and PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), of which were selected only clinical trials of phase 
II and III, in patients of female gender, published in the last five years, which addressed any 
drug for the treatment of osteoporosis. 
After inclusion and exclusion criteria, of the 132 studies, 34 were selected to be included in 
the systematic review. These trials included drugs of different pharmacologic profiles. 
Regarding drugs with anabolic effects, molecules which stimulate bone formation, clinical 
trials show efficacy for Romosozumab and BA 058, while for MK-5442 the results were 
unsatisfactory. Regarding bone antiresorptive drugs, Denosumab was reported in several 
studies to have high efficacy. Other further promising drugs included ONO-5334 and 
Odanacatib, which showed positive results in several clinical trials. 
Despite the wide diversity of drugs under clinical trials, new pharmacological options should 
be developed to revert bone loss in this highly prevalent chronic disease. 
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